PB 124 of 2025

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2025 (No. 10)

National Health Act 1953

I, REBECCA RICHARDSON, Assistant Secretary, PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under subsection 98C(1) of the National Health Act 1953.

Dated 29 October 2025

REBECCA RICHARDSON
Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division

Contents

1. Name...............................................1

2. Commencement.........................................1

3. Authority.............................................1

4. Schedules............................................1

Schedule 1—Amendments............................................2

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)              2

 

Commencement information

 

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1. The whole of this instrument

1 November 2025

1 November 2025

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)

[1] Schedule 3, after entry for Methylphenidate in the form Capsule containing methylphenidate hydrochloride 10 mg (modified release) (s19A)

insert:

Methylphenidate

Capsule containing methylphenidate hydrochloride 10 mg (modified release) (Switzerland) (S19A)

[2] Schedule 3, after entry for Methylphenidate in the form Capsule containing methylphenidate hydrochloride 20 mg (modified release) (s19A)

insert:

Methylphenidate

Capsule containing methylphenidate hydrochloride 20 mg (modified release) (Switzerland) (s19A)

[3] Schedule 3, after entry for Methylphenidate in the form Capsule containing methylphenidate hydrochloride 30 mg (modified release) (s19A)

insert:

Methylphenidate

Capsule containing methylphenidate hydrochloride 30 mg (modified release) Ritalin LA (Switzerland) (s19A)

Methylphenidate

Capsule containing methylphenidate hydrochloride 30 mg (modified release) (Switzerland) (s19A)

[4] Schedule 3, after entry for Methylphenidate in the form Capsule containing methylphenidate hydrochloride 40 mg (modified release)

insert:

Methylphenidate

Capsule containing methylphenidate hydrochloride 40 mg (modified release) (Switzerland) (s19A)

[5] Schedule 4, omit entry for Betaxolol

[6] Schedule 4, entries for Estradiol with norethisterone

(a) omit:

Estradiol with norethisterone

Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 (S19A)

(b) omit:

Estradiol with norethisterone

Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 (S19A)